Short Interest in Starpharma Holdings Ltd. (OTCMKTS:SPHRY) Declines By 99.0%

Starpharma Holdings Ltd. (OTCMKTS:SPHRY) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 1 shares, a decrease of 99.0% from the August 15th total of 101 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 769 shares, the days-to-cover ratio is presently 0.0 days.

Starpharma Price Performance

Starpharma stock remained flat at $5.35 during mid-day trading on Thursday. 1,000 shares of the company’s stock traded hands, compared to its average volume of 644. Starpharma has a one year low of $0.74 and a one year high of $5.82. The business has a 50-day moving average of $4.98 and a two-hundred day moving average of $4.49.

About Starpharma

Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.

In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.